Table of Content



1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Country Snapshot
2.3. Country Analysis
2.4. Key Growth Enablers
2.5. Key Challenges

3. Key Analytics
3.1. Porter’S Five Forces Analysis
3.1.1. Threat Of New Entry
3.1.2. Threat Of Substitution
3.1.3. Buyer’S Power
3.1.4. Supplier’S Power
3.1.5. Competitive Rivalry
3.2. Impact Of Covid-19 On Non-Alcoholic Steatohepatitis (Nash) Biomarker Market
3.3. Opportunity Matrix
3.4. Vendor Landscape
3.5. Key Investment Insights

4. Market By Type
4.1. Serum Biomarker
4.2. Hepatic Fibrosis Biomarker
4.3. Apoptosis Biomarker
4.4. Oxidative Stress Biomarker
4.5. Other Types

5. Market By End-User
5.1. Pharma & Cro Industry
5.2. Diagnostic Lab
5.3. Academic Research Key
5.4. Hospital

6. Competitive Landscape
6.1. Key Strategic Developments
6.1.1. Merger & Acquisitions
6.1.2. Product Launch & Developments
6.1.3. Partnership, Contract/Agreement & Collaboration
6.1.4. Business Expansion/ Approval/ Announcement
6.2. Company Profile
6.2.1. Bristol-Myers Squibb Company
6.2.2. Gilead Sciences Inc
6.2.3. Madrigal Pharmaceuticals
6.2.4. Merck & Co
6.2.5. Pfizer Inc



List of Figures


Figure 1: Porter’S Five Force Analysis
Figure 2: Opportunity Matrix
Figure 3: Vendor Landscape
Figure 4: Key Investment Insights
Figure 5: United States Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Type, In 2020
Figure 6: United States Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Serum Biomarker, 2021-2026 (In $ Million)
Figure 7: United States Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Hepatic Fibrosis Biomarker, 2021-2026 (In $ Million)
Figure 8: United States Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Apoptosis Biomarker, 2021-2026 (In $ Million)
Figure 9: United States Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Oxidative Stress Biomarker, 2021-2026 (In $ Million)
Figure 10: United States Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Other Types, 2021-2026 (In $ Million)
Figure 11: United States Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By End-User, In 2020
Figure 12: United States Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Pharma & Cro Industry, 2021-2026 (In $ Million)
Figure 13: United States Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Diagnostic Lab, 2021-2026 (In $ Million)
Figure 14: United States Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Academic Research Key, 2021-2026 (In $ Million)
Figure 15: United States Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Hospital, 2021-2026 (In $ Million)


List of Tables


List of Tables


TABLE 1: MARKET SNAPSHOT - NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER
TABLE 2: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 3: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, FORECAST YEARS, 2021-2026 (IN $ MILLION)
TABLE 4: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 5: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, FORECAST YEARS, 2021-2026 (IN $ MILLION)